Brief: Immunocore's Tebentafusp Granted Breakthrough Therapy Designation

Immunocore Holdings

19/02/2021 12:18

Feb 19 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE’S TEBENTAFUSP GRANTED BREAKTHROUGH THERAPY
DESIGNATION FOR UNRESECTABLE OR METASTATIC UVEAL MELANOMA FROM
FDA

Source text for Eikon:  ID:nGNX1JqZdt 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))